Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study of andexanet alfa as a reversal agent for edoxaban

Trial Profile

A phase III study of andexanet alfa as a reversal agent for edoxaban

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Andexanet alfa (Primary)
  • Indications Haemorrhage
  • Focus Registrational; Therapeutic Use
  • Acronyms ANNEXA-E
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 06 May 2015 According to a Portola Pharmaceuticals media release, final data from this and the other two phase III ANNEXA studies (see profiles 700242840 and 700238727) is expected to be presented in 2015.
    • 12 Aug 2014 New trial record
    • 06 Aug 2014 Portola Pharmaceuticals plans to initiate ANNEXA-E registration studies in 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top